Drug Profile
Quercetin - Quercegen Pharmaceuticals
Alternative Names: Q Force; QU995™Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Beijing Chemical Reagent Factory; Catholic University of the Sacred Heart - Rome; Farr Laboratories LLC; Indiana University School of Medicine; Quercegen Pharmaceuticals; Singapore General Hospital; SRI International; Taiyuan Pharmaceutical Factory; University of Birmingham; University of California at Los Angeles; University of Ulster
- Developer National Institutes of Health (USA); Quercegen Pharmaceuticals; University of Michigan
- Class Flavonoids; Small molecules
- Mechanism of Action Antioxidants; Enzyme inhibitors; Free radical scavengers; Platelet aggregation inhibitors; Prostaglandin synthase stimulants; Protein tyrosine kinase inhibitors; Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
- Discontinued Atherosclerosis; Cancer; Cardiovascular disorders; Prostatitis
Most Recent Events
- 01 Nov 2023 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (PO) (NCT06003270)
- 09 Sep 2023 Pharmacodynamics data from the preclinical trial for chronic obstructive pulmonary disease presented at the 33rd Annual Congress of the European Respiratory Society 2023 (ERS-2023)
- 21 Aug 2023 Temple University in collaboration with Quercegen Pharmaceuticals, NIH and National center for complementary and integrative health (NCCIH) plans a phase II trial for Chronic obstructive pulmonary disease in USA (PO) in September 2023 (NCT06003270)